CL2021000729A1 - Derivados de indano para el uso en el tratamiento de infección bacteriana - Google Patents
Derivados de indano para el uso en el tratamiento de infección bacterianaInfo
- Publication number
- CL2021000729A1 CL2021000729A1 CL2021000729A CL2021000729A CL2021000729A1 CL 2021000729 A1 CL2021000729 A1 CL 2021000729A1 CL 2021000729 A CL2021000729 A CL 2021000729A CL 2021000729 A CL2021000729 A CL 2021000729A CL 2021000729 A1 CL2021000729 A1 CL 2021000729A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- bacterial infection
- indane derivatives
- indane
- antibiotics
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 125000003392 indanyl group Chemical class C1(CCC2=CC=CC=C12)* 0.000 title 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 2
- 229940088710 antibiotic agent Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 abstract 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a un compuesto que es un indano de acuerdo con la Fórmula (I), o una sal farmacéuticamente aceptable del mismo, donde R1, R2, R3, R4, R5, R6, L, n y p son como se definen en la presente. Los compuestos son útiles en el tratamiento de infección antibacteriana ya sea como antibióticos independientes, o en combinación con antibióticos adicionales.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18290106.6A EP3628666A1 (en) | 2018-09-25 | 2018-09-25 | Indane derivatives for use in the treatment of bacterial infection |
EP18290104 | 2018-09-26 | ||
EP18197365 | 2018-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000729A1 true CL2021000729A1 (es) | 2021-11-05 |
Family
ID=67439236
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000729A CL2021000729A1 (es) | 2018-09-25 | 2021-03-24 | Derivados de indano para el uso en el tratamiento de infección bacteriana |
CL2021000731A CL2021000731A1 (es) | 2018-09-25 | 2021-03-24 | Derivados de indano para uso en el tratamiento de infección bacteriana |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000731A CL2021000731A1 (es) | 2018-09-25 | 2021-03-24 | Derivados de indano para uso en el tratamiento de infección bacteriana |
Country Status (14)
Country | Link |
---|---|
US (2) | US20220112169A1 (es) |
EP (2) | EP3856730A1 (es) |
JP (2) | JP7429993B2 (es) |
KR (2) | KR20210087448A (es) |
CN (2) | CN113166085B (es) |
AU (2) | AU2019351551A1 (es) |
BR (2) | BR112021005532A2 (es) |
CA (2) | CA3113697A1 (es) |
CL (2) | CL2021000729A1 (es) |
IL (2) | IL281780A (es) |
MA (2) | MA53706A (es) |
MX (2) | MX2021003485A (es) |
SG (2) | SG11202102791SA (es) |
WO (2) | WO2020064174A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113166085B (zh) * | 2018-09-25 | 2024-04-09 | 安塔比奥公司 | 用于治疗细菌感染的茚满衍生物 |
US20240016941A1 (en) * | 2020-03-24 | 2024-01-18 | Antabio Sas | Combination therapy |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457196A (en) * | 1991-09-27 | 1995-10-10 | Merrell Dow Pharmaceuticals Inc. | 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
JP3126541B2 (ja) * | 1993-03-26 | 2001-01-22 | 千寿製薬株式会社 | ベンゾチアゾール誘導体、その製法及びその用途 |
JPH0782259A (ja) * | 1993-09-14 | 1995-03-28 | Senju Pharmaceut Co Ltd | スクシンアミド酸誘導体及びそれを含有する糖尿病合併症治療剤 |
JPH11130761A (ja) * | 1997-10-24 | 1999-05-18 | Otsuka Pharmaceut Co Ltd | ベンゾチアゾール誘導体 |
AU2005282466B2 (en) | 2004-09-08 | 2011-03-10 | Merck Sharp & Dohme Corp. | Monocyclic anilide spirolactam CGRP receptor antagonists |
FR2883876B1 (fr) | 2005-03-30 | 2007-05-04 | Servier Lab | Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2006125511A1 (de) | 2005-05-25 | 2006-11-30 | Merck Patent Gmbh | Pyran-dioxan-derivate und deren verwendung in flüssigkristallinen medien |
KR101583487B1 (ko) | 2007-06-05 | 2016-01-08 | 사노피 | 치환된 벤조일아미노-인단-2-카복실산 및 관련된 화합물 |
EP2141164A1 (en) * | 2008-07-01 | 2010-01-06 | Mutabilis | New 1,2,4-triazine derivatives and biological applications thereof |
US8877815B2 (en) * | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
MX2015006328A (es) * | 2012-11-30 | 2015-09-07 | Bayer Cropscience Ag | Mezcla fungicida o pesticida binaria. |
GB201704476D0 (en) * | 2017-03-21 | 2017-05-03 | Antabio Sas | Chemical compounds |
CN113166085B (zh) | 2018-09-25 | 2024-04-09 | 安塔比奥公司 | 用于治疗细菌感染的茚满衍生物 |
-
2019
- 2019-07-25 CN CN201980066561.2A patent/CN113166085B/zh active Active
- 2019-07-25 WO PCT/EP2019/070116 patent/WO2020064174A1/en unknown
- 2019-07-25 US US17/277,535 patent/US20220112169A1/en active Pending
- 2019-07-25 MX MX2021003485A patent/MX2021003485A/es unknown
- 2019-07-25 CA CA3113697A patent/CA3113697A1/en active Pending
- 2019-07-25 KR KR1020217012348A patent/KR20210087448A/ko unknown
- 2019-07-25 EP EP19744710.5A patent/EP3856730A1/en active Pending
- 2019-07-25 AU AU2019351551A patent/AU2019351551A1/en active Pending
- 2019-07-25 JP JP2021540370A patent/JP7429993B2/ja active Active
- 2019-07-25 BR BR112021005532-0A patent/BR112021005532A2/pt unknown
- 2019-07-25 US US17/277,649 patent/US20210347748A1/en active Pending
- 2019-07-25 MX MX2021003498A patent/MX2021003498A/es unknown
- 2019-07-25 BR BR112021005651-3A patent/BR112021005651A2/pt unknown
- 2019-07-25 KR KR1020217012349A patent/KR20210087025A/ko active Search and Examination
- 2019-07-25 SG SG11202102791SA patent/SG11202102791SA/en unknown
- 2019-07-25 CA CA3113689A patent/CA3113689A1/en active Pending
- 2019-07-25 MA MA053706A patent/MA53706A/fr unknown
- 2019-07-25 WO PCT/EP2019/070115 patent/WO2020064173A1/en unknown
- 2019-07-25 CN CN201980063308.1A patent/CN113166084B/zh active Active
- 2019-07-25 SG SG11202102790PA patent/SG11202102790PA/en unknown
- 2019-07-25 JP JP2021540369A patent/JP7429992B2/ja active Active
- 2019-07-25 EP EP19744709.7A patent/EP3856729A1/en active Pending
- 2019-07-25 MA MA053707A patent/MA53707A/fr unknown
- 2019-07-25 AU AU2019349438A patent/AU2019349438A1/en active Pending
-
2021
- 2021-03-24 CL CL2021000729A patent/CL2021000729A1/es unknown
- 2021-03-24 CL CL2021000731A patent/CL2021000731A1/es unknown
- 2021-03-24 IL IL281780A patent/IL281780A/en unknown
- 2021-03-24 IL IL281770A patent/IL281770A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202102790PA (en) | 2021-04-29 |
JP7429993B2 (ja) | 2024-02-09 |
CN113166085A (zh) | 2021-07-23 |
EP3856730A1 (en) | 2021-08-04 |
JP2022502485A (ja) | 2022-01-11 |
KR20210087025A (ko) | 2021-07-09 |
KR20210087448A (ko) | 2021-07-12 |
JP2022502486A (ja) | 2022-01-11 |
WO2020064173A1 (en) | 2020-04-02 |
CN113166085B (zh) | 2024-04-09 |
MA53707A (fr) | 2021-12-29 |
US20210347748A1 (en) | 2021-11-11 |
SG11202102791SA (en) | 2021-04-29 |
CN113166084A (zh) | 2021-07-23 |
CL2021000731A1 (es) | 2021-11-05 |
IL281770A (en) | 2021-05-31 |
BR112021005651A2 (pt) | 2021-06-22 |
IL281780A (en) | 2021-05-31 |
MX2021003485A (es) | 2021-09-10 |
EP3856729A1 (en) | 2021-08-04 |
US20220112169A1 (en) | 2022-04-14 |
MX2021003498A (es) | 2021-09-10 |
CA3113689A1 (en) | 2020-04-02 |
MA53706A (fr) | 2021-12-29 |
BR112021005532A2 (pt) | 2021-06-29 |
AU2019349438A1 (en) | 2021-04-15 |
WO2020064174A1 (en) | 2020-04-02 |
CA3113697A1 (en) | 2020-04-02 |
CN113166084B (zh) | 2024-06-04 |
AU2019351551A1 (en) | 2021-04-15 |
JP7429992B2 (ja) | 2024-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020012824A2 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma | |
ECSP18005828A (es) | Inhibidores de metalo-beta-lactamasa | |
DOP2022000117A (es) | Inhibidores de kras g12c | |
CL2020003260A1 (es) | Compuestos de naftiridinona sustituidos útiles como activadores de células t | |
BR112017011941A2 (pt) | compostos 5-amino-6h-tiazol [4,5-d] pirimidina-2,7-diona substituídos 3 para o tratamento e profilaxia de infecção viral | |
CO2019000932A2 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
CL2021001190A1 (es) | Compuestos de azalactam como inhibidores de hpk1 | |
CO2019005534A2 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
UY38428A (es) | Nuevos compuestos antihelmínticos | |
CL2021000729A1 (es) | Derivados de indano para el uso en el tratamiento de infección bacteriana | |
CY1125004T1 (el) | Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας | |
CL2020001147A1 (es) | Compuestos antibacterianos | |
CL2020002139A1 (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado. | |
CL2020003380A1 (es) | Compuestos que aumentan la actividad del proteosoma. | |
CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
CL2020002157A1 (es) | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. | |
CL2020000553A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso. | |
CL2017001276A1 (es) | Derivados de benzotiazol antibacterianos | |
CL2020003248A1 (es) | Derivados de tetrahidrotienopiridina n-sustituidos y sus usos | |
CO2020016080A2 (es) | Compuestos | |
BR112017015744A2 (pt) | composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas | |
UY39579A (es) | COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS | |
PE20200333A1 (es) | Compuestos y metodos para tratar infecciones bacterianas | |
BR112019002195A2 (pt) | inibidores de beta-lactamase |